Sonnet Biotherapeutics Holdings Inc. announced that it has received a notice from The Nasdaq Stock Market LLC indicating non-compliance with the minimum stockholders' equity requirement for continued listing on The Nasdaq Capital Market. The company reported stockholders' equity of $662,262, falling short of the required $2,500,000. Sonnet does not meet alternative compliance standards either, such as a market value of listed securities of at least $35 million or net income of $500,000. Nasdaq has given Sonnet until July 14, 2025, to submit a plan to regain compliance, with a possible extension of up to 180 days if the plan is accepted. The company's stock will continue trading under the symbol "SONN" as it explores options to meet the listing requirements. There are no assurances that the company's plan will be accepted or that it will successfully regain compliance.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。